DUBLIN, June 24, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/f9mqvw/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering.
Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three approved products namely Alcon Laboratories's Durezol, Allergan's Ozurdex, and Bausch & Lomb's Retisert.
The expected entry of new players such as Lux Biosciences's Luveniq (NDA filled), pSivida Corp.'s Medidur (phase III), and Santen Pharmaceutical Co. Ltd.'s DE-109 (phase III) within the forecast period is expected to intensify the competition in future. The products currently available in the market are associated with low safety and as those products do not serve the market's unmet need, the market continues to present opportunities for stronger pipeline candidates.
According to the report, one of the main drivers in this market is the increasing prevalence of eye disorders around the world, which has consequently led to a rise in the incidence of uveitis. Uveitis is responsible for approximately 5 to 20 percent of legal blindness in western countries and approximately 25 percent of blindness in the developing world.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
07. Market Landscape
08. Treatment Options for Uveitis
09. Pipeline Snapshot
10. Rate of Incidence and Prevalence
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
21. Other Reports in this Series
- Abbvie Inc.
- Alcon Laboratories Inc.
- Allergan Inc.
- Bausch & Lomb Inc.
- Artielle ImmunoTherapeutics Inc.
- Enzo Biochem Inc.
- Hanall Pharmaceutical Co. Ltd.
- Lux Biosciences Inc.
- OphthaliX Inc.
- Regeneron Pharmaceuticals Inc.
- pSivida Corp.
- XOMA Corp.
- Santen Pharmaceutical Co.
For more information visit http://www.researchandmarkets.com/research/f9mqvw/global_uveitis
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets